Peter Rothschild, President of BioGaia, summarises 2015 and answers questions regarding;
- reasons behind a weaker trend during the fourth quarter
- any possible factors that may affect sales during the upcoming year
- what needs to be accomplished in order to reach doubel-digit growth also the next year
- the proposed listing of subsidary IBT and the progress they are making in developing a new drug against NEC
- expectations, oportunities and challenges for the upcoming year